Objectives. To identify all of the patients affected by chronic hepatitis C infection treated with TNF-a blockers (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab) in order to evaluate the safety profile.
Introduction
HCV has been the major cause of chronic liver disease worldwide since 1989, with an estimated worldwide prevalence of 2.2% (1.3 Â 10 9 HCV-positive persons worldwide), and is the most common blood-borne infection in the USA [1, 2] . Geographical variations in prevalence are well known; low rates of HCV seroprevalence are found in the UK (0.01%), Germany (0.6%), Canada (0.8%), India (0.9%), France (1.1%) and Australia (1.1%) [13] . Higher rates have been reported in the USA [with 3.9 million (1.8%) of the population infected], Japan (1.52.3%), Italy (2.2%), China (3.2%) and Egypt (22%) [13] . HCV infection is implicated in the rising incidence of hepatocellular carcinoma (HCC) in many countries, such as Japan, Spain, France and Italy [14] . HCV chronic liver disease accounts for the development of 27% of cases of cirrhosis and 25% of the cases of HCC worldwide [2] . Therefore, prevention of HCV infection remains the key factor for public health intervention, without ignoring the benefits of anti-viral therapy in eradicating the virus and the benefit of avoiding hepatotoxic agents [3] .
Chronic inflammatory diseases such as RA, Crohn's disease (CD), ulcerative colitis (UC), AS, psoriasis and PsA are frequently found in the US and European populations. Considering the psoriasis prevalence of 13% in the USA, the estimated prevalence of both psoriasis and HCV occurring simultaneously is 0.020.06% in this population ($55 000150 000 persons in the USA) [5] . For RA, the prevalence in the US population is estimated at 1% [6] . So, the prevalence of both RA and HCV occurring simultaneously is 0.02% between all age groups ($55 000 persons in the USA) [6] . Evidence of HCV infection in patients with CD has an estimated prevalence of 7.4% in Italy, 2.3% in France and 0.79% in Spain [7] . In our daily practice, we face an increasing number of patients concomitantly affected by HCV infection and chronic inflammatory diseases susceptible to be treated with TNF-a blockers.
Treatment of chronic inflammatory conditions such as IBD, RA, AS, PsA and psoriasis in the setting of chronic HCV infection can be quite difficult because many traditional therapies may aggravate hepatitis and increase viraemia [713] . On the other hand, anti-HCV therapy, particularly IFN-a, can aggravate or induce psoriasis, PsA, RA, polyarthropathy and IBD (even if there is a lack of definitive evidence regarding IBD) [713] .
In the past 13 years, anti-TNF-a agents have emerged as an effective therapy for a wide spectrum of chronic inflammatory diseases. Infliximab is a recombinant humanmurine chimeric immunoglobulin-G1 (IgG1) antibody that specifically binds both soluble and membrane-bound precursor forms of TNF-a [14] . Actually, infliximab is Food and Drug Administration (FDA) approved for psoriasis, PsA, RA, adult and paediatric CD, AS and UC [14] . Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kDa TNF receptor linked to the Fc portion of the human IgG1 [15] . Etanercept is FDA approved for RA, polyarticular-course JIA, PsA, AS and adult and paediatric psoriasis [15] . Adalimumab is a human-derived recombinant IgG1 mAb that binds to TNF-a, but not TNF-b and blocks the interaction between soluble TNF-a and cell-surface TNF receptors [16] . Adalimumab is FDA approved for RA, polyarticular-course JIA, adult CD, PsA, AS and psoriasis [16] . Golimumab is a human IgG1K mAb that binds to both the soluble and transmembrane bioactive forms of human TNF-a [17] . Golimumab is actually approved for RA, PsA and AS [17] . Certolizumab pegol is a pegylated Fab-9 fragment of a humanized anti-TNF-a antibody that binds to TNF-a, blocking the interaction with cell surface receptors [18] . Certolizumab is currently approved for RA and CD [18] . Hepatotoxicity during anti-TNF-a therapy is an uncommon side effect that can sometimes be life threatening [19] . In the post-marketing surveillance phase, FDA has reported 134 patients with liver failure associated either with infliximab or etanercept; in particular, FDA has highlighted seven patients in whom other causes of liver failure were excluded and regression of the liver failure occurred after drug suspension [19, 20] . In the current article, we present a systematic literature review that identified patients with HCV infection who were concomitantly treated with anti-TNF-a agents, in order to assess the safety of these treatments.
Methodology
We performed a systematic search of English language databases (PubMed, Embase and Web of Science) from January 1990 until October 2010, using the following keywords and [MESH FORMS]: 'hepatitis C' and/or 'tumor necrosis factor or anti tumor necrosis factor alpha' and/ or 'TNF' and/or 'etanercept' and/or 'infliximab' and/or 'adalimumab' and/or 'golimumab' and/or 'certolizumab' and/or 'psoriasis' and/or 'Crohn's disease' and/or 'rheumatoid arthritis' and/or 'psoriatic arthritis' and/or 'ulcerative colitis' and/or 'ankylosing spondylitis' and/or 'liver toxicity'. No exclusion criteria were applied.
Results
We retrieved 37 publications describing a total of 153 patients (157 cycles of therapy) who were treated with anti-TNF-a agents in the setting of HCV infection, between the years 1999 and 2010 [2157] . The patients were evaluated for the following variables: disease, comorbidities, HCV genotype, anti-TNF-a treatment (drug, duration and dosage), previous HCV treatment (drug, duration and dosage), concomitant treatments (drug, duration and dosage), liver enzymes (before, during and after anti-TNF-a treatment), HCV viral load (before, during and after anti-TNF-a treatment), histopathological liver reports (before, during and after anti-TNF-a treatment), complications and outcomes.
The mean anti-TNF-a treatment duration in the setting of HCV infection was 11.9 months (range: 1 dose to 60 months) [ [21, 3537, 39, 43, 45, 56] , and one patient was treated with IFN and allograft liver transplant [45] . Three patients with psoriasis received concomitant etanercept and IFNRBV therapy (Table 2) [42, 55] . Other concomitant and potentially hepatotoxic therapies that were administered simultaneously during anti-TNF-a therapy are stated in Table 2. HCV-related liver disease outcomes during and after anti-TNF-a therapy for psoriasis and PsA were not available in one patient [35] ; in one patient who was previously treated with IFNRBV the HCV viral load and levels of transaminases remained stable during and after treatment with infliximab and then adalimumab [37] . In four patients, improvements in viral load and the levels of transaminases were reported (Table 2) [36, 39, 45] , and one of the patients who was concomitantly treated with etanercept and IFNRBV had complete and sustained viral remission after 6 months of therapy (Table 2 ). In 17 patients who were treated with etanercept, viral load and/or the levels of transaminases were reported as stable [21, 30, 3638, 40, 41, 43, 44] (Table 2 ). In one patient treated with etanercept, viral load increased more than 1 Â log 10 with stable liver enzymes levels [56] .
HCV-related liver disease outcomes after anti-TNF-a therapy for RA In the context of RA, 61 patients were treated with etanercept, 24 with infliximab and 8 with adalimumab and in 5 patients, treatment with etanercept or infliximab was reported [2234] . For detailed information on these patients, see Table 3 . In patients with RA, HCV-related liver disease was reported to be stable (stable HCV viral load and/or stable levels of transaminases) in 83 patients, 50 of whom were treated with etanercept [23, 2732, 34] . Of the remaining 33 patients, 5 were treated with etanercept or infliximab [24] , 19 were treated with infliximab [20, 24, 28, 30, 58] and 9 received adalimumab [27, 29, 30 ]. An improvement in HCV viral load and/or the levels of transaminases was described in two patients with RA who were treated with etanercept [26, 31] ; one of these patients was also concomitantly treated with IFNRBV [26] . Worsening of previous levels of transaminases, without HCV viral load increase was reported in one patient under etanercept and an increase in HCV viral load was described in seven patients who were treated with anti-TNF-a agents; four of these patients were treated with etanercept [22, 32, 33] and three were treated with infliximab [32, 33] . In one patient, described by Pritchard [22] , a 12-fold increase in viral load was accompanied by a 3-fold increase in the levels of transaminases, which was reversed after the suspension of etanercept treatment. Li et al.
[34] described one patient with a 3-fold increase in transaminases and a 4-fold increase in HCV viral load after switching treatment from etanercept to infliximab. Regarding anti-HCV treatment, one patient received previous IFN therapy [31] and another patient received concomitant etanercept and IFNRBV therapy with sustained virological remission [26] (Table 3) . Other concomitant and potentially hepatotoxic therapies that were administered simultaneously during ant-TNF-a therapy are stated in Table 3. HCV-related liver disease outcomes after anti-TNF-a therapy for CD and other inflammatory conditions HCV-related liver disease outcomes during and after treatment with anti-TNF-a agents for other diseases such as CD [4650] , AS [37], cryoglobulinaemia [51] , vasculitis [52] , HCV-related oligo-and polyarthritis [54] and Khanna et al. Oniankitan et al. [25] RA ( (Tables 4  and 5 ). Other concomitant and potentially hepatotoxic therapies that were administered simultaneously during ant-TNF-a therapy are stated in Tables 4 and 5 .
Zein et al. [53] conducted a double-blind, randomized, placebo-controlled trial involving 50 patients who were chronically infected with HCV; the patients received either placebo and IFNRBV therapy (n = 25) or etanercept and IFNRBV therapy (n = 19) for 24 weeks. At Week 24, 63% (n = 12) of patients receiving etanercept had negative HCV viral loads compared with 32% (n = 8) of the placebo arm (P = 0.04) [53] . At Week 72, 42% (n = 8) of patients receiving etanercept had a sustained virological and biochemical response compared with 32% (n = 8) of patients receiving placebo. The latter difference did not reach statistical significance, but the trial additionally demonstrated that etanercept was not associated with serious toxic effects in HCV-infected patients [53] .
Worsening of the HCV vial load and/or elevation of liver enzyme levels and/or histological demonstration of hepatic worsening between the different diseases studied (psoriasis, RA, CD and other chronic inflammatory conditions) was 8.8% (three patients under infliximab and five patients under etanercept) between patients affected by RA and 4.2% (one patient under etanercept) between patients affected by psoriatic disease (psoriasis and/or PsA) (P = 1.0, Fisher's exact test). No alterations were reported in patients suffering from CD or other inflammatory conditions (20 patients).
Discussion
The treatment of severe, chronic inflammatory conditions in the setting of HCV infection remains a difficult therapeutic challenge because of the risk that treatment of the inflammatory condition could aggravate hepatitis and increase viraemia. On the other hand, anti-HCV therapy such as IFN-a can aggravate the underlying disease [912] . Aggressive immunosuppression frequently leads to an increase in the levels of HCV viral load and worsening of liver conditions in transplant patients [4] . Many therapies, including MTX and acitretin, have the potential to induce hepatotoxicity [23, 24] , meaning that we often face difficult-to-treat patients who require systemic treatments in the setting of chronic HCV infection and TNF-a-blocking agents might represent a valid option for treatment in these patients.
TNF-a is produced by hepatocytes in patients who are chronically infected with HCV and may play a role in regulating viral replication or hepatocyte damage [4, 5962] . Increased titres of TNF-a have been associated with high levels of transaminases in patients with chronic HCV infection [4] . An imbalance in the numbers of circulating Th1 and Th2 lymphocytes has been implicated in the progression of infection in HCV-infected patients [4] . In patients in whom the acute response to HCV infection is mediated by Th1 lymphocytes, with the predominant production of IFN-g, the self-limited response against the infection appears to be optimal; in contrast, patients whose response is primarily mediated by a Th2 response become chronically infected [4, 59] . Patients with high titres of TNF-a before treatment with IFN-a respond to a lesser extent than those who have low titres of TNF-a [4, 59] .
TNF-a appears to be implicated in a patient's biological resistance to anti-HCV therapy, as demonstrated by Tsai et al. [59] . Treatment with IFN increases secretion of the soluble portion of the TNF-a receptor (sTNF-R p55) that naturally inhibits serum TNF-a [59] . It seems that the inhibitory effect of TNF-a on T-cell proliferation and activation is the key factor for resistance to IFN-a therapy. Blockade of TNF may also stimulate the reactivity of peripheral T cells to specific antigens, for example microbial antigens, and increase the anti-HCV effect of IFN-a [4, 5962].
To date, the vast majority of the literature that supports the use of TNF-a-blocking agents in patients who are chronically infected with HCV comes from case reports and case series (level of evidence 3); only one Phase II, randomized, controlled trial (level of evidence 2 or more) has been published regarding the safety of anti-TNF-a therapies in patients with chronic HCV infection [2157] . It is worth noting that, to date, controlled clinical trials evaluating the use of anti-TNF-a therapies in conditions as diverse as RA and psoriasis have excluded patients with chronic HCV infection from participation.
The safety profile of anti-TNF-a agents in the setting of HCV infection appears to be acceptable, considering that only two cases of confirmed or probable HCV liver disease worsening among 153 patients treated with anti-TNF-a agents for a mean of 11.9 months, have been reported until now. One case of confirmed HCV liver disease worsening (with hepatic improvement after withdrawal of etanercept) among 110 patients treated with etanercept and one probable case among 34 patients treated with infliximab (case not confirmed by liver biopsy or by suspension of infliximab and improvement of the HCV viral load and transaminases levels) can be found in the literature. In the other five patients, increases in the levels of transaminases did not correspond to increased viral loads and vice versa and liver biopsies were not executed [32, 33, 56] . As shown here, most of Campbell et al. [46] CD ( Infliximab therapy in the setting of HCV has been reported in 34 patients, with stable liver outcomes cited in 21 patients, improvement in HCV liver conditions in three patients, and complete and sustained viral remission after combination treatment with infliximab and IFNRBV in one patient [50] . A fatal outcome was reported due to disseminated aspergillosis in one patient, probably related to immunosuppression, and due to severe HCV-related vasculitis in two patients in whom infliximab was not effective in controlling the systemic inflammatory disease [50, 52] .
The frequency of liver HCV condition alteration (worsening of the HCV vial load and/or elevation of liver enzyme levels and/or histological demonstration of hepatic worsening) between the different diseases studied (psoriatic disease, RA, CD and other chronic inflammatory conditions), was 8.8% among patients affected by RA and 4.2% among patients affected by psoriatic disease. No alterations were reported in patients suffering from CD or other inflammatory conditions. The difference in the frequency of liver alterations did not reach statistical significance (P = 1.0) and can only be a bias related to the small number of patients treated with other diseases different from RA (91 patients with RA vs 62 with other different disease), but could also be related to chronic co-medications frequently received by RA patients (MTX, CSs, NSAIDS and AZA) or to a different pattern of hepatic susceptibility. Regarding the susceptibility to hepatic toxicity, RA patients in comparison with psoriasis patients seem to have at least the same or a better tolerability profile to treatment with MTX and a recent study demonstrated that type of disease (RA vs psoriasis) had no influence on susceptibility to liver damage [63, 64] . The experience with adalimumab in the setting of HCV infection is restricted to reports of nine patients. All of the studies found a stable level of transaminases and HCV viral loads during treatment [27, 29, 32, 34, 37] .
It must be noted that, in 2004, a warning was added to the package insert of infliximab stating that 'severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis, have been reported in postmarketing data in patients receiving [infliximab] . Autoimmune hepatitis has been diagnosed in some of these cases. Some of these cases were fatal or necessitated liver transplantation' [19] . No such FDA warnings of hepatotoxicity have been issued regarding the use of adalimumab, etanercept, golimumab or certolizumab. Of four patients who have been affected by toxic hepatitis induced by infliximab, the absence of cross-toxicity with etanercept has been reported in three patients and the absence of such reactivity after switching to adalimumab has also been reported in one case [6568] . Interestingly, no hepatoxicity-related events were associated with pre-existing viral hepatitis.
In the absence of long-term, large, controlled clinical trials, a definitive statement regarding the safety of anti-TNF-a therapies in the setting of chronic HCV infection cannot be made [19, 2257] . A consensus statement of 2008 regarding the use of anti-TNF-a therapies for the treatment of rheumatic diseases in the setting of HCV infection, recommends screening of all patients before TNF-a-blocking agent initiation, because the long-term safety of these agents in patients with chronic HCV infection is unknown [69] . But the consensus statement does not provide a clear indication for the use of anti-TNF-a therapies in the setting of chronic HCV infection, nor a clear contraindication and in daily clinical practice physicians continue to use these therapies without a standardized follow-up schedule.
At present, etanercept is the biological agent that has been most frequently used in the clinical setting in patients with a chronic HCV infection. A possible explanation for the use of different biological treatments in the setting of HCV infection may be the different hepatotoxicity profiles (as reported by the FDA) of each agent, the different patterns of clinical use and the fact that more literature supports the use of etanercept in the setting of HCV infection [19] .
For prognostic purposes, the liver biopsy is the only reliable method to obtain information regarding fibrosis stage in routine clinical practice [70] . HCV-RNA quantification is useful to monitor virological responses to anti-viral therapy [70] . Normal fluctuations in HCV-RNA load have been reported, with <1 log variations when levels are monitored at monthly intervals and with a maximum of three peaks of HCV-RNA increase (defined as >50% increase) with a median change of 1 log [71] . Aminotransferase and HCV RNA fluctuations are regularly asynchronous and liver histology does not show significant correlation with the replication activity of the virus [71] . Pre-treatment screening for HCV infection should be performed in all candidates for anti-TNF-a therapy, as already proposed by national guidelines from the USA and UK [72, 73] . Consultation with a liver specialist may be appropriate before starting anti-TNF-a therapy [73] . Monitoring of patients eligible for anti-TNF-a therapy in the setting of a chronic HCV infection should be made with pre-treatment liver biopsy, monthly aminotransferase levels and periodic quantitative HCV RNA [70, 71] . A liver biopsy is indicated in cases of sustained increase of aminotransferase levels and HCV viral load (>1 log) in order to better quantify any liver damage [70, 71] .
HCV chronic hepatitis is a major risk factor for cirrhosis and HCC, and immunosuppression may accelerate this progression. Long-term treatment with anti-TNF-a therapies and long-term evaluation of patient outcomes has not yet been performed with significant numbers of patients who have chronic HCV infections; thus, careful and well-followed schedules should be proposed for patients with HCV infection who require systemic therapy with these agents. Long-term, prospective trials are needed in order to quantify the safety of anti-TNF-a therapies in the setting of chronic HCV infection.
Rheumatology key messages
. The safety profile of TNF-a blockers in the setting of HCV seems to be acceptable. . Differences in the hepatotoxic profile are apparent between different agents. . TNF-a may play a role in regulating viral replication or hepatocyte damage.
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